Freeline Therapeutics Holdings PLC
NASDAQ:FRLN
Freeline Therapeutics Holdings PLC
Cash from Operating Activities
Freeline Therapeutics Holdings PLC
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Freeline Therapeutics Holdings PLC
NASDAQ:FRLN
|
Cash from Operating Activities
-$78.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash from Operating Activities
-$160.3m
|
CAGR 3-Years
-147%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash from Operating Activities
-$145.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash from Operating Activities
-$85.1m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Operating Activities
£2.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Cash from Operating Activities
£44.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
See Also
What is Freeline Therapeutics Holdings PLC's Cash from Operating Activities?
Cash from Operating Activities
-78.5m
USD
Based on the financial report for Dec 31, 2022, Freeline Therapeutics Holdings PLC's Cash from Operating Activities amounts to -78.5m USD.
What is Freeline Therapeutics Holdings PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-14%
Over the last year, the Cash from Operating Activities growth was 27%. The average annual Cash from Operating Activities growth rates for Freeline Therapeutics Holdings PLC have been -14% over the past three years .